The glioblastoma multiforme market is expected to witness a significant positive shift owing to the positive outcomes of the several products during the developmental stage by key players such
(1)
LAS VEGAS, March 4, 2021 /PRNewswire/ Rare cancers account for approximately 22% of all the diagnosed cancer cases. The US National Cancer Institute defines rare cancers as those with an incidence of less than 15 cases per 100?000 per year.
However, these cases are not confined to one or the other particular geography, but are disproportionately spread across the world. Many rare human cancers are not curable, and have limited number of treatment options. Rare cancers are more difficult to diagnose and are often misdiagnosed. Rarity of the cancers further complicates the running of clinical trials. Lack of clinical expertise, research, and funding are other barriers in the Rare cancer market.